Our proven experience and capabilities within the complexity of the European market for 40 years have made us the partner of choice for CNS products in Europe.
Our purpose is to offer a comprehensive and specialized range of CNS therapeutic solutions to improve the lives and well-being of our patients daily.
We have a broad CNS portfolio to meet our patients’ needs across CNS, covering chronic, severe and standard disorders such as psychosis and schizophrenia, depression, epilepsy and anxiety, among others. More than 90% of our sales are in CNS.
At Neuraxpharm, we have a strong focus on innovation to provide a wide range of proven and differentiated treatment options to meet all patients’ and HCP’s needs, from standard generics, value added medicines and originator brands to the more innovative such as orphan drugs, beyond-the-pill solutions and biologic drugs.
Neuraxpharm is the leading European platform with an exclusive focus on the treatment of the central nervous system (CNS), reaching 98% of the European CNS market. We have a direct presence in more than 23 countries in Europe with our own affiliates to make sure we cover the key markets.
Our headquarters are split between Germany and Spain. In Spain, our manufacturing facilities and R&D hub provide the necessary activities to successfully launch and commercialize CNS products in Europe.
We have a strong commercial organization with coverage of the key CNS specialists (especially in the field of neurology and psychiatry) in hospitals, clinics, centers and other HCPs such as hospital pharmacies.
With a highly adaptable structure for different molecules and projects, our field force visits ~75% of the relevant CNS target group.
We have a strong expertise in successfully launching CNS products to market thanks to our Scientific Center of Excellence, “Neuraxpharm HealthTech”, which combines our multi-functional team from R&D, clinical, regulatory affairs and medical affairs.
We also have a fully dedicated market access platform, with national expertise in the key CNS markets, to optimize reimbursement in Europe and ensure patients have access to our products, while considering the idiosyncrasies of each market.
We combine in-depth knowledge of the local markets, strong strategic Corporate guidance and flexibility to adapt the CNS specialized organization fast to business needs. As an example, we have created a specialized Business Unit for BRIUMVI®.
Our product engine is fueled by internal development, licensing and acquisition projects (Mergers & Acquisitions) focused on innovative solutions to enrich our portfolio. We have successfully brought 25 pipeline projects (Business Development and R&D) to the market in the last 5 years, and this has been a strong growth driver.
Neuraxpharm is a vertically integrated company from molecule to market, with an attractive asset-light business model. It also has in-house manufacturing and extensive experience collaborating with CMOs (Contract Manufacturing Organization) worldwide.
Neuraxpharm has a global presence in more than 50 countries through partners and distributors and with affiliates in LATAM (Brazil and Mexico), in the Middle East and Australia. These cover the key markets and deliver a comprehensive range of CNS therapeutic solutions to improve the lives of millions of patients worldwide.
Partnering in a few figures
Key Innovation Partners
Key partners
